This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization For The Treatment Of Certain Patients With Chronic Tophaceous Gout

BRIDGEWATER, N.J. and DUBLIN, Jan. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Ltd., today announced that the European Commission has granted a marketing authorization for KRYSTEXXA ® (pegloticase) for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

"There is currently no other treatment option in the EU for patients with severe chronic tophaceous gout who do not respond to oral xanthine oxidase inhibitors," said Dr. Thomas Bardin, MD, Professor and Head of the Rheumatology department at the Lariboisière Hospital in Paris, France.  "KRYSTEXXA addresses a significant unmet medical need and represents an important development for healthcare professionals and European patients suffering from this debilitating disease."   

"European approval of KRYSTEXXA demonstrates our ongoing commitment to this underserved population by offering a much needed treatment option to these patients and marks a significant milestone for the Company," said Lou Ferrari, President and Chief Executive Officer of Savient. "We continue to establish relationships with clinicians and key opinion leaders in Europe, and we anticipate product launch in the region by mid-2013."

The European Commission's approval decision was based upon safety and efficacy data from Savient's two pivotal Phase III studies, and a long-term open label extension study of KRYSTEXXA, as well as non-clinical and chemistry, manufacturing and control information.  

Until the product becomes commercially available in the EU, Savient will continue to provide KRYSTEXXA to patients through the established Named Patient Programme (NPP).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs